Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT03202875
- Locations
- 🇩🇪
Investigational Site 276001, Neuss, Germany
An Observational Study on Teriflunomide-exposed Pregnancies
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 220
- Registration Number
- NCT03198351
- Locations
- 🇺🇸
University of California at San Diego-Site Number:001, San Diego, California, United States
🇨🇦Investigational Site Number :002, Canada, Canada
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 109
- Registration Number
- NCT03194867
- Locations
- 🇬🇷
Investigational Site Number :3000001, Athens, Greece
🇨🇦Investigational Site Number :1240003, Sherbrooke, Quebec, Canada
🇮🇹Investigational Site Number :3800003, Brescia, Italy
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
- Conditions
- Malignant Solid Tumor
- Interventions
- Biological: SAR439459
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 161
- Registration Number
- NCT03192345
- Locations
- 🇧🇪
Investigational Site Number : 0560001, Leuven, Belgium
🇺🇸Tennessee Oncology, PLLC Site Number : 8400006, Nashville, Tennessee, United States
🇺🇸Mary Crowley Cancer Research Center Site Number : 8400003, Dallas, Texas, United States
A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT03174548
- Locations
- 🇬🇧
Investigational Site Number 826001, Leeds, United Kingdom
Observational Study Describing the Immune Profile Induced By Pertussis Vaccines
- Conditions
- PertussisWhooping Cough
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT03147898
- Locations
- 🇵🇦
Investigational Site, Panama City, Panama
An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 179
- Registration Number
- NCT03099213
- Locations
- 🇮🇩
Sanofi Administrative Office, Bali, Indonesia
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
- Conditions
- End-stage Renal Disease
- Interventions
- Biological: Rabbit Anti-thymocyte Immunoglobulin
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 115
- Registration Number
- NCT03099122
- Locations
- 🇨🇳
CHINA, China, China
Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT03070678
- Locations
- 🇫🇷
Investigational site 250001, Gières, France
PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT03069963
- Locations
- 🇫🇷
Investigational Site Number 2500001, Gieres, France